Investors Financial Results

Investors

Latest Announcements

Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines

25 MAR 2025 | READ MORE

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)

20 MAR 2025 | READ MORE

Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India

12 MAR 2025 | READ MORE

Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)

10 MAR 2025 | READ MORE

Glenmark Pharmaceuticals Inc., USA launches acquires and launches Acetylcysteine Injection 6 gm-30 mL (200 mg-mL) Single-Dose Vials

03 MAR 2025 | READ MORE

Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial

27 FEB 2025 | READ MORE

Q3 FY 2025 Results - Newspaper Advertisement

17 FEB 2025 | READ MORE

Press Release and Management Discussion & Analysis

14 FEB 2025 | READ MORE

Outcome of the Board Meeting – Change in Directorate

14 FEB 2025 | READ MORE

U.S. FDA inspection at the Company's Facility at Indore, Madhya Pradesh, India

14 FEB 2025 | READ MORE

Glenmark Pharma reports consolidated revenue growth of 35.1%, EBITDA margin of 17.7% and PAT margin of 10.3% YoY for Q3 FY2025

14 FEB 2025 | READ MORE

Unaudited Financial Results (Standalone and Consolidated) for the Third Quarter and Nine Months ended 31st December, 2024

14 FEB 2025 | READ MORE

Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution 0.005%

14 FEB 2025 | READ MORE

Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%

12 FEB 2025 | READ MORE

Intimation under Regulation 30 of SEBI LODR

08 FEB 2025 | READ MORE

Q3 FY 25 Earnings Call Invitation – 17 February 2025

05 FEB 2025 | READ MORE

Board Meeting Intimation – 14 February 2025

03 FEB 2025 | READ MORE

Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules

21 JAN 2025 | READ MORE

Intimation of change in the name of the Step Down Wholly Owned Subsidiaries of the Company

08 JAN 2025 | READ MORE

Update on acquisition of securities of O2 Renewable Energy XXIV Private Limited

18 DEC 2024 | READ MORE

First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

10 DEC 2024 | READ MORE

Q2 FY 2025 Results - Newspaper Advertisement

18 NOV 2024 | READ MORE

Press Release and Management Discussion & Analysis

14 NOV 2024 | READ MORE

Unaudited Financial Results (Standalone and Consolidated) for the Second Quarter and Half Year ended 30th September, 2024

14 NOV 2024 | READ MORE

Q2 FY 25 Earnings Call Invitation – 18 November 2024

07 NOV 2024 | READ MORE

Board Meeting Intimation – 14 November 2024

30 OCT 2024 | READ MORE

Outcome and Result of AGM

27 SEP 2024 | READ MORE

Newspaper Advertisement

05 SEP 2024 | READ MORE

Newspaper Advertisement

03 SEP 2024 | READ MORE

Notice of 46th Annual General Meeting

03 SEP 2024 | READ MORE

AGM Date Intimation

27 AUG 2024 | READ MORE

Glenmark’s Q1 FY 2024 - 25 Results –
Newspaper Advertisement

16 AUG 2024 | READ MORE

Glenmark’s Q1 FY 2024-25 Results

14 AUG 2024 | READ MORE

Glenmark’s Press Release and MDA Q1 FY 2024-25

14 AUG 2024 | READ MORE

Glenmark’s Investor Presentation Q1 FY 2024-25

14 AUG 2024 | READ MORE

Glenmark Pharma reports consolidated revenue growth of 6.9%, EBITDA margin of 18.1%, and PAT margin of 10.5% YoY for Q1 FY 2024-25

14 AUG 2024 | READ MORE

Q1 FY 25 Earnings Call Invitation – August 16, 2024

05 AUG 2024 | READ MORE

Board Meeting Intimation – 14 August 2024

31 JULY 2024 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg

17 JULY 2024 | READ MORE

Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)

12 JUNE 2024 | READ MORE

Glenmark’s Q4 FY 2023-24 Results –
Newspaper Advertisement

29 MAY 2024 | READ MORE

Outcome of Board Meeting – Results, Dividend & Appointment of Cost Auditors

24 MAY 2024 | READ MORE

Glenmark Pharma Reports Q4 FY2023-24 Financial results

24 MAY 2024 | READ MORE

Glenmark Pharma MDA Q4 FY2023-24

24 MAY 2024 | READ MORE

Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India

21 MAY 2024 | READ MORE

Investor Day intimation

17 MAY 2024 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%

17 MAY 2024 | READ MORE

Q4 FY 24 Earnings Call Invitation – May 27, 2024

15 MAY 2024 | READ MORE

Board Meeting Intimation – 24 May 2024

15 MAY 2024 | READ MORE

Intimation of Acquisition

13 MAY 2024 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC)

29 APR 2024 | READ MORE

Credit Ratings -rating rationale issued by India Ratings and Research

25 APR 2024 | READ MORE

Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2024

11 APR 2024 | READ MORE

Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2024

02 APR 2024 | READ MORE

Retirement of Independent Directors

01 APR 2024 | READ MORE

Credit Ratings - rating research update issued by CRISIL Ratings

20 MAR 2024 | READ MORE

Credit Ratings -rating research update issued by S&P Global ratings

13 MAR 2024 | READ MORE

Disclosure pursuant to Regulation 30(7) of SEBI LODR

13 MAR 2024 | READ MORE

Disclosure pursuant to Regulation 30(7) of SEBI LODR

07 MAR 2024 | READ MORE

Intimation of Schedule of Analyst-Institutional investor meeting, February 2024

19 FEB 2024 | READ MORE

Glenmark’s Q3 FY 2023-24 Results – Newspaper Advertisement

16 FEB 2024 | READ MORE

Glenmark’s Q3 FY 2023-24 Results

14 FEB 2024 | READ MORE

Glenmark’s MDA Q3 FY 2023 – 24

14 FEB 2024 | READ MORE

Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24

14 FEB 2024 | READ MORE

Allotment of Equity Shares under Glenmark Pharmaceuticals Limited ESOP Scheme 2016

13 FEB 2024 | READ MORE

Q3 FY 24 Earnings Call Invitation – February 16, 2024

02 FEB 2024 | READ MORE

Glenmark partners with Pfizer to launch Abrocitinib in India

31 JAN 2024 | READ MORE

Board Meeting Intimation – 14 February 2024

31 JAN 2024 | READ MORE

Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance ‐ ‘Ichnos Glenmark Innovation’

30 JAN 2024 | READ MORE

Jiangsu Alphamab Biopharmaceuticals, 3D Medicines (Beijing) and Glenmark announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

25 JAN 2024 | READ MORE

Glenmark is the first to launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India

03 JAN 2024 | READ MORE
Financial Results Icon

SHAREHOLDERS CORNER

Be a part of the new world

KNOW MORE
About Us - Governance

GOVERNANCE

The principles that govern us

KNOW MORE
Investors Report Icon

REPORTS AND PRESENTATION

Performance in numbers

KNOW MORE
About Us Thumbnail

About Us

Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future

KNOW MORE